Cargando…

A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence

INTRODUCTION: Adverse drug reaction (ADR) is a public health problem which constitutes one of the leading causes of morbidity and mortality worldwide. In India, only a few studies reported cancer chemotherapy-induced ADRs. The objectives of the present study were to assess the organ system involved,...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Pramod Kumar, Misra, Arup Kumar, Gupta, Ajay, Singh, Surjit, Dhamija, Puneet, Pareek, Puneet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302695/
https://www.ncbi.nlm.nih.gov/pubmed/30636831
http://dx.doi.org/10.4103/ijp.IJP_544_17
_version_ 1783382035311624192
author Sharma, Pramod Kumar
Misra, Arup Kumar
Gupta, Ajay
Singh, Surjit
Dhamija, Puneet
Pareek, Puneet
author_facet Sharma, Pramod Kumar
Misra, Arup Kumar
Gupta, Ajay
Singh, Surjit
Dhamija, Puneet
Pareek, Puneet
author_sort Sharma, Pramod Kumar
collection PubMed
description INTRODUCTION: Adverse drug reaction (ADR) is a public health problem which constitutes one of the leading causes of morbidity and mortality worldwide. In India, only a few studies reported cancer chemotherapy-induced ADRs. The objectives of the present study were to assess the organ system involved, frequency, severity, and preventability of the ADRs occurred. MATERIALS AND METHODS: Data on ADRs of retrospective cohorts were extracted from the filled ADR forms received from the department of radiation oncology. Descriptive statistic was used to summarize and analyze the available data, namely patient demography, causality, severity, and preventability of the event. RESULTS: A total of 191 chemotherapy-induced ADR reports were received from 164 patients during the period March 2015 to August 2017. Almost three-fourth of the ADRs occurred in patients who were receiving regimens involving multiple drugs. Taxanes, alkylating agents, and platinum compounds were the common drug groups involved. The skin (n = 90) was the most frequently involved organ with alopecia and hyperpigmentation as most common manifestations. The severity (Hartwig and Siegel) and preventability scales (Modified Schumock and Thornton) indicated that most reactions were mild (54.45%) in nature and the majority of them were preventable. More than two-third (69%) of the reactions were related “possible” to the suspected drug as determined by the World Health Organization causality assessment. CONCLUSION: Chemotherapy-related ADRs among cancer patients are worrisome. It has a negative impact on patient quality of life and in addition increases cost of therapy. It is found that timely reporting of chemotherapy-related ADRs and having an effective ADR monitoring system in place ensure preventability of the ADRs in many cases. Oncologists, Radiotherapists and Onco-surgeons should be actively involved in ADR reporting (Onco-Pharmacovigilance) and exchange constructive information, update and educate each other about appropriate use of anticancer drugs. Onco-pharmacovigilance is the need of the hour and could be of immense value in reducing morbidity and mortality if practiced with utmost importance.
format Online
Article
Text
id pubmed-6302695
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-63026952019-01-11 A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence Sharma, Pramod Kumar Misra, Arup Kumar Gupta, Ajay Singh, Surjit Dhamija, Puneet Pareek, Puneet Indian J Pharmacol Research Article INTRODUCTION: Adverse drug reaction (ADR) is a public health problem which constitutes one of the leading causes of morbidity and mortality worldwide. In India, only a few studies reported cancer chemotherapy-induced ADRs. The objectives of the present study were to assess the organ system involved, frequency, severity, and preventability of the ADRs occurred. MATERIALS AND METHODS: Data on ADRs of retrospective cohorts were extracted from the filled ADR forms received from the department of radiation oncology. Descriptive statistic was used to summarize and analyze the available data, namely patient demography, causality, severity, and preventability of the event. RESULTS: A total of 191 chemotherapy-induced ADR reports were received from 164 patients during the period March 2015 to August 2017. Almost three-fourth of the ADRs occurred in patients who were receiving regimens involving multiple drugs. Taxanes, alkylating agents, and platinum compounds were the common drug groups involved. The skin (n = 90) was the most frequently involved organ with alopecia and hyperpigmentation as most common manifestations. The severity (Hartwig and Siegel) and preventability scales (Modified Schumock and Thornton) indicated that most reactions were mild (54.45%) in nature and the majority of them were preventable. More than two-third (69%) of the reactions were related “possible” to the suspected drug as determined by the World Health Organization causality assessment. CONCLUSION: Chemotherapy-related ADRs among cancer patients are worrisome. It has a negative impact on patient quality of life and in addition increases cost of therapy. It is found that timely reporting of chemotherapy-related ADRs and having an effective ADR monitoring system in place ensure preventability of the ADRs in many cases. Oncologists, Radiotherapists and Onco-surgeons should be actively involved in ADR reporting (Onco-Pharmacovigilance) and exchange constructive information, update and educate each other about appropriate use of anticancer drugs. Onco-pharmacovigilance is the need of the hour and could be of immense value in reducing morbidity and mortality if practiced with utmost importance. Medknow Publications & Media Pvt Ltd 2018 /pmc/articles/PMC6302695/ /pubmed/30636831 http://dx.doi.org/10.4103/ijp.IJP_544_17 Text en Copyright: © 2018 Indian Journal of Pharmacology http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Research Article
Sharma, Pramod Kumar
Misra, Arup Kumar
Gupta, Ajay
Singh, Surjit
Dhamija, Puneet
Pareek, Puneet
A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence
title A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence
title_full A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence
title_fullStr A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence
title_full_unstemmed A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence
title_short A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence
title_sort retrospective analysis of reporting of adverse drug reactions to oncology drugs: an experience from a national center of clinical excellence
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302695/
https://www.ncbi.nlm.nih.gov/pubmed/30636831
http://dx.doi.org/10.4103/ijp.IJP_544_17
work_keys_str_mv AT sharmapramodkumar aretrospectiveanalysisofreportingofadversedrugreactionstooncologydrugsanexperiencefromanationalcenterofclinicalexcellence
AT misraarupkumar aretrospectiveanalysisofreportingofadversedrugreactionstooncologydrugsanexperiencefromanationalcenterofclinicalexcellence
AT guptaajay aretrospectiveanalysisofreportingofadversedrugreactionstooncologydrugsanexperiencefromanationalcenterofclinicalexcellence
AT singhsurjit aretrospectiveanalysisofreportingofadversedrugreactionstooncologydrugsanexperiencefromanationalcenterofclinicalexcellence
AT dhamijapuneet aretrospectiveanalysisofreportingofadversedrugreactionstooncologydrugsanexperiencefromanationalcenterofclinicalexcellence
AT pareekpuneet aretrospectiveanalysisofreportingofadversedrugreactionstooncologydrugsanexperiencefromanationalcenterofclinicalexcellence
AT sharmapramodkumar retrospectiveanalysisofreportingofadversedrugreactionstooncologydrugsanexperiencefromanationalcenterofclinicalexcellence
AT misraarupkumar retrospectiveanalysisofreportingofadversedrugreactionstooncologydrugsanexperiencefromanationalcenterofclinicalexcellence
AT guptaajay retrospectiveanalysisofreportingofadversedrugreactionstooncologydrugsanexperiencefromanationalcenterofclinicalexcellence
AT singhsurjit retrospectiveanalysisofreportingofadversedrugreactionstooncologydrugsanexperiencefromanationalcenterofclinicalexcellence
AT dhamijapuneet retrospectiveanalysisofreportingofadversedrugreactionstooncologydrugsanexperiencefromanationalcenterofclinicalexcellence
AT pareekpuneet retrospectiveanalysisofreportingofadversedrugreactionstooncologydrugsanexperiencefromanationalcenterofclinicalexcellence